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The epidermal growth factor receptor (EGFR) has becomean important target in the treatment of non-small cell lung
cancer (NSCLC). A number of drugs have been developed
that are designed to inhibit EGFR including a monoclonal
antibody, cetuximab, and small molecule tyrosine kinase
inhibitors (TKIs) such as gefitinib and erlotinib. Mutations in
EGFR and K-ras and EGFR expression by immunohisto-
chemistry (IHC) and fluorescent in situ hybridization (FISH)
have all been evaluated as scientific correlates in trials using
these agents. There is great interest in understanding the
clinical parameters and biomarkers that predict for survival
benefit and drug resistance.
SUMMARY OF PRESENTATIONS
The EGFR-TKIs have usually been used in the second-
line setting, and biomarkers have been evaluated in an ex-
ploratory fashion. In the ISEL trial that compared gefitinib
with placebo, both EGFR mutations (exon 19 deletion and
exon 21 L858R) and EGFR high copy number predicted for
higher response rate.1 The INTEREST trial compared ge-
fitinib to docetaxel in a similar patient population.2 Again the
response rate was higher for patients treated with gefitinib
who were EGFR mutation or FISH. Overall survival was
similar for gefitinib and docetaxel irrespective of EGFR gene
copy, EGFR protein expression, EGFR, or K-ras mutational
status. Interestingly, EGFR mutations did predict for a better
progression-free survival for patients treated with gefitinib on
both trials. In the IPASS trial, east Asian patients who were
never or light smokers were randomized to receive chemo-
therapy or gefitinib as first-line treatment.3 Patients who were
EGFR mutation benefited more from gefitinib, whereas the
mutation negative patients did better with chemotherapy,
indicating a role for mutation testing if an EGFR-TKI is used
as initial treatment.
The EGFR-TKIs have not been successfully combined
with chemotherapy in unselected, untreated patients. A ran-
domized phase II trial prospectively selected patients who
were EGFR IHC and/or EGFR FISH to receive erlotinib
or erlotinib and chemotherapy.4 Activating EGFR mutations
and absence of K-ras both suggested a better survival for all
patients, whereas EGFR FISH patients trended toward a better
survival with erlotinib.5 The MARVEL trial will categorize
patients receiving second-line therapy on the basis of EGFR
FISH. Both positive and negative patients will be independently
randomized to receive either pemetrexed or erlotinib.
Cetuximab as an antibody to EGFR may work differ-
ently from the TKIs. On S0342, chemotherapy was combined
with concurrent or sequential cetuximab.6 Although there was
little difference in outcome between the two study arms
patients who had a high EGFR, copy number by FISH had a
better response rate and survival. Two phase III trials, FLEX
and BMS 099, combined chemotherapy  cetuximab in the
treatment of chemonaive patients with NSCLC.7,8 Patients on
the FLEX trial had to be EGFR by IHC and patients who
received the cetuximab had a modest but significant survival
benefit. On the BMS 099 trial, there was no patient selection
and no survival advantage for the cetuximab arm. A number
of molecular markers were evaluated on the BMS trial, and
none of the markers including EGFR FISH and K-ras were
predictive of benefit or lack there of. It is clear that validation
of the EGFR FISH biomarker is warranted.
There are a number of other large trials that are using
the EGFR-TKIs. Many of these trials are collecting tissue and
serum and stratifying patients for molecular markers in an
attempt at validation of their predictive potential. In the TITAN
trial, patients are treated with standard platin-based chemother-
apy. Those who progress are randomized to chemotherapy or
erlotinb, whereas those who do not progress (SATURN) are
randomized to placebo or maintenance erlotinib. The ATLAS
trial is evaluating erlotinib  bevacizumab versus bevaci-
zumab as maintenance after initial chemotherapy.
There are now a number of new generation EGFR
inhibitors. BIBW 2992 is an oral irreversible TKI of both
EGFR and HER2, and it demonstrates activity in EGFR
mutants resistant to erlotinb, gefitinib, and lapatinib. It has
demonstrated single agent activity in patients with EGFR
mutations (LUX-Lung 2), and a trial is underway evaluating
the drug in EGFR TKI failures (LUX-Lung 1). Additional
trials are planned comparing the drug with chemotherapy as
initial treatment and combining it with cetuximab in patients
who have developed resistance to gefitinib or erlotinib. IMC-
11F8 is a fully human IgG1 antibody with an epitope similar
to cetuximab. It is currently being evaluated in clinical trials
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in colon and lung cancer. IMC-3G3 is an antibody against
PDGFR currently in phase I evaluation. Phase II trials are
being planned in a number of tumor types. EVRI (BMS-
690514) is a dual inhibitor of ErbB and VEGFR2 and is a
potent inhibitor of EGFR and VEGFR signaling. In a phase I
trial with a phase II expansion in NSCLC toxicities were
manageable, and there was activity in erlotinib naive and
refractory patients. Phase I trials in combination with chemo-
therapy are being planned in NSCLC and colon cancer.
PF-00299804 is a PanHER TKI that is a potent inhibitor of all
HER receptor TKs and has activity in sensitive and resistant
EGFR/HER2 driven xenograft models. In a phase II expan-
sion trial in NSCLC after phase I, the drug had activity in
patients with T790M mutations. There are a number of
ongoing phase II trials in NSCLC in erlotinib refractory
patients, second/third line versus erlotinib, and first line in
never or light smokers.
FUTURE DIRECTIONS
It is of utmost importance to determine the molecular
markers that define sensitivity and resistance to EGFR inhib-
itors. This is difficult because of inconsistencies among
techniques and laboratories used to determine various bi-
omarkers and the lack of patient tumor tissue. Molecular
characterization of circulating tumors cells may provide a
strategy for noninvasive monitoring of tumor genotypes dur-
ing treatment.9 By using a microfluidic device containing
microposts coated with antibodies against epithelial cells,
EGFR mutations can be detected accurately from circulating
tumor cells. Matrix-assisted laser desorption ionization mass
spectrometry has been used on patient serum to identify those
likely to benefit from EGFR TKIs.10 S0709 is a phase II trial
of erlotinb  chemotherapy in proteomic positive NSCLC
patients. These new technologies and new drug development
along with rational clinical trial designs will hopefully ad-
vance the field and improve the treatment of lung cancer.
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